STOCKS TELEGRAPH

Tag: CATB

  • Why Catabasis Pharmaceuticals Inc (CATB) stock surged in the after-market on Tuesday?

    Why Catabasis Pharmaceuticals Inc (CATB) stock surged in the after-market on Tuesday?

    Catabasis Pharmaceuticals Inc. (CATB) shares soared 29.9% in after-market on Tuesday, June 15, 2021, and closed the session at $2.65 per share. Earlier in the morning session, CATB’s stock lost 3.32% to close Tuesday’s session at $2.04 per share. CATB shares have fallen 69.82% over the last 12 months, and they have moved down 5.56% in the past week. Over the past three months, the stock has lost 42.70%, while over the past six months, it has declined 7.69%.

    Let’s see is there any recent news or development about CATB?

                Participation in the investor conferences

    • Catabasis Pharmaceuticals Inc recently participated in the Jefferies Virtual Healthcare Conference which held on June 3, 2021.
    • The company also took part in Oppenheimer Rare and Orphan Disease Summit which held on May 21, 2021.
    • At both conferences, the company was presented by Chief Executive Officer Jill C. Milne.

    Recent financial results

    On May 14, 2021, Catabasis Pharmaceuticalsreported financial results for the first quarter ended March 31, 2021.

    Q1 2021 financial highlights

    • For Q1 2021, research and development expenses were $2.6 million compared to $5.3 million for the three months ended March 31, 2020.
    • General and administrative expenses were $2.9 million for Q1 2021 compared to $2.8 million for Q1 2020.
    • Operating loss for Q1 2021 was $170.1 million compared to $8.0 million for Q1 2020.
    • The company suffered a net loss of $170.1 million, or $7.60 per share, for the three months ended March 31, 2021, compared to a net loss of $8.0 million, or $0.50 per share, for the three months ended March 31, 2020.
    • Catabasis had cash, cash equivalents, and short-term investments of $146.9 million on March 31, 2021, compared to $44.9 million as of December 31, 2020.

    Q4&FY2020 financial results

    On March 12, 2021, Catabasis Pharmaceuticals released its financial results for the fourth quarter and full-year ended December 31, 2020. 

    Q4 2020 financial highlights

    • Catabasis had cash, cash equivalents, and short-term investments of $44.9 million on December 31, 2021, compared to $52.9 million as of September 30, 2020.
    • For Q4 2020, Research and development expenses were $5.7 million compared to $4.3 million for Q4 2019.
    • General and administrative expenses were $3.2 million for Q4 2020 compared to $2.5 million for the three months ended December 31, 2019
    • Operating loss was $9.0 million for Q4 2020 compared to $6.7 million for Q4 2019.
    • Catabasis suffered a net loss of $9.0 million, or $0.45 per share in Q4 2020 compared to a net loss of $6.6 million, or $0.55 per share, for the three months ended December 31, 2019.

    FY-2020 financial highlights

    • Research and development expenses were $25.6 million for the full year 2020, compared to $18.3 million for the full year 2019.
    • For the full year 2020, general and administrative expenses were $11.9 million compared to $8.8 million for the full year 2019.
    • For FY 2020, operating loss was $37.4 million compared to $27.1 million for the full year 2019.
    • Catabasis suffered a net loss of$37.3 million, or $2.03 per share, for the full year 2020, compared to $26.3 million, or $2.35 per share, for the full year 2019.

    Conclusion

    Well, as of this writing there is no recent news or development so the CATB stock surge is a bit strange.

  • Biotech Roundup &The delivery of the Pfizer’s vaccine to U.S. – starts Today

    Biotech Roundup &The delivery of the Pfizer’s vaccine to U.S. – starts Today

    This weekend, the U.S. government is packaging millions of doses of the coronavirus vaccine from Pfizer and BioNTech for distribution to places around the country, a mammoth logistics task in favor of what could be the most difficult immunization campaign in history.

    In delivering the vaccine, which is delicate and needs careful care, FedEx and UPS would play key roles. At the terminal, shipments can gain preferential entry. If a plane arrives to land with vaccinations, other passenger flights may have to loop around to wait for their chance.

    The arrival of the first vaccines comes as the virus continues to rage through the USA, with more than 207,000 new cases identified on Saturday by authorities. That took the number to more than 16 million, the most in the world by far. For the first time on Wednesday, more than 3,000 deaths were reported, and the country’s number is nearing 300,000.

    vTv Therapeutics Inc. (NASDAQ:VTVT) shares were trading up 41.55% at $3.10 at the time of writing on Friday. The firm on November 25, 2020 announced common stock purchase agreement for up to $47 million with Lincoln Park Capital.

    vTv Therapeutics Inc. (NASDAQ:VTVT) share price went from a low point around $1.44 to briefly over $4.23 in past 52 weeks, though shares have since pulled back to $3.10. VTVT market cap has remained high, hitting $161.79M at the time of writing, giving it price-to-sales ratio of more than 7350.

    If we look at the recent analyst rating VTVT, H.C. Wainwright initiated coverage on VTVT shares with a Buy rating.

    aTyr Pharma Inc. (LIFE) last closed at $4.64, in a 52-week range of $2.13 to $7.62. The company on November 13, 2020 released third quarter results and provided a corporate update.

    ADiTx Therapeutics Inc. (ADTX) stock soar by 3.77% to $2.48. The firm reported on December 8, 2020, that it will present at the 13th annual LD Micro main event conference on Tuesday, December 15, 2020 at 11:00 AM EST / 8:00 AM PST.

    9 Meters Biopharma Inc. (NASDAQ:NMTR) Shares headed falling, lower as much as -11.75%.

    Iterum Therapeutics plc (NASDAQ:ITRM) rose 11.72% after gaining more than $0.1 on Friday. The biotechnology firm declared on December 7,2020, filing of US patent application based on favorable written opinion of the International Search Authority.

    Vaxart Inc. (VXRT) last closed at $7.44, in a 52-week range of $0.28 to $17.49.

    Catabasis Pharmaceuticals Inc. (CATB) stock soar by 14.51% to $2.21. The most recent rating by Wedbush, on November 02, 2020, is at a Neutral.

    Advaxis Inc. (NASDAQ:ADXS) Shares headed rising, higher as much as 3.56%. The company on November 27, 2020 reported the closing of $9.2 million public offering. The most recent rating by Barclays, on August 03, 2016, is at an Overweight.

    Xeris Pharmaceuticals Inc. (NASDAQ:XERS) rose 11.74% after gaining more than $0.48 on Friday following an announcement from the company that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive Opinion for Ogluo™ (glucagon).

    Novavax Inc. (NVAX) last closed at $124.88, in a 52-week range of $3.65 to $189.40. The firm on December 9, 2020, declared the appointment of Margaret G. McGlynn, R. Ph. to its board as an independent director. Analysts have a consensus price target of $186.20.

    Corbus Pharmaceuticals Holdings Inc. (CRBP) stock soar by 1.52% to $1.34. The most recent rating by ROTH Capital, on September 08, 2020, is at a Neutral.

    Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares headed falling, lower as much as -1.23%. The most recent rating by Mizuho, on April 22, 2020, is at a Neutral.

    Novan Inc. (NASDAQ:NOVN) rose 1.10% after gaining more than $0.01 on Friday.

    Nabriva Therapeutics plc (NBRV) last closed at $2.44, in a 52-week range of $3.26 to $18.29. The company recently announced pricing of $15 million public offering.

    Salarius Pharmaceuticals Inc. (SLRX) stock drop by -31.34% to $0.92 after declaring that it has entered into agreements with several institutional and accredited investors to exercise of warrants for $3.5 million of gross proceeds to be used for ongoing development of Seclidemstat. The most recent rating by Ladenburg Thalmann, on April 27, 2020, is at a Buy.